Withdrawal of cerivastatin from the world market

被引：276

作者：

Furberg, CD ^{[1
]}

Pitt, B

机构：

[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA

[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA

来源：

CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE | 2001年 / 2卷 / 05期

关键词：

cerivastatin; drug safety; LDL cholesterol; rhabdomyolysis; statins;

D O I：

10.1186/CVM-2-5-205

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three important questions raised by this withdrawal. Should we continue to approve drugs on surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We conclude that decisions regarding the use of drugs should be based on direct evidence from long-term clinical outcome trials.

引用

页码：205 / 207

页数：3

共 9 条

[1]

*AM HEART ASS AM C, 2001, ACC AHA REASS PAT ST

[2]

D'Agostino Ralph B Jr, 2000, Curr Control Trials Cardiovasc Med, V1, P76, DOI 10.1186/CVM-1-2-076

[3]

FUHRMANS V, 2001, WALL ST J 0809, pA3

[4]

Furberg CD, 2001, CURR CONTR TRIALS C, V2, P107

[5] Natural statins and stroke risk [J].

Furberg, CD .

CIRCULATION, 1999, 99 (02) :185-188

[6]

Pfeffer MA, 2001, EUR HEART J, V22, P271

[7] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Fye, CL ;

Anderson, JW ;

Elam, MB ;

Faas, FH ;

Linares, E ;

Schaefer, EJ ;

Schectman, G ;

Wilt, TJ ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :410-418

[8] Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study [J].

Schlesinger, Z ;

Vered, Z ;

Friedenson, A ;

Reisin, L ;

Jafari, J ;

Flieb, T ;

Sclarovsky, S ;

Friedman, Y ;

Ostfeld, B ;

Solodky, A ;

Abinader, E ;

Rochfleish, S ;

Palant, A ;

Schneider, H ;

Rosenfeld, T ;

Khalid, S ;

Wolfson, E ;

Kishon, Y ;

Narinsky, R ;

Rotzak, R ;

Davidov, A ;

Levine, G ;

Zahavi, I ;

Vitrai, J ;

Diker, D ;

Pelled, B ;

Pardu, J ;

Galamidi, J ;

Majadla, R ;

Laniado, S ;

Sherf, L ;

Braun, S ;

Eschar, Y ;

Caspi, A ;

Arditi, A ;

Botwin, S ;

Arkavi, L ;

Ziv, M ;

David, D ;

Weisenberg, D ;

Kohanovski, M ;

Meisel, S ;

Rougin, N ;

Yahalom, M ;

Glusman-Vazan, A ;

Markiewitz, W ;

Motlak, D ;

Lessick, J ;

Kagan, G ;

Marmour, A .

CIRCULATION, 2000, 102 (01) :21-27

[9] Bayer faces potential fine over cholesterol lowering drug [J].

Tuffs, A .

BRITISH MEDICAL JOURNAL, 2001, 323 (7310) :415-415

← 1 →